Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk

Journal of Psychopharmacology
Michael RoereckeJ Rehm

Abstract

Reduction of long-term mortality risk, an important clinical outcome for people in alcohol dependence treatment, can rarely be established in randomized controlled trials (RCTs). We calculated the reduction in all-cause mortality risk using data from short-term (6 and 12 months) double-blind RCTs comparing as-needed nalmefene treatment to placebo, and mortality risks from meta-analyses on all-cause-mortality risk by reduction of drinking in people with alcohol dependence. A reduction in drinking in the RCTs was defined by shifts in drinking risk levels established by the European Medicines Agency. Results showed that the reduction of drinking in the nalmefene group was associated with a reduction in mortality risk by 8% (95% CI: 2%, 13%) when compared to the placebo group. Sensitivity analyses confirmed a significant effect. Thus comparing the difference between nalmefene and placebo in reduction in drinking levels with results on all-cause mortality risk from meta-analyses indicated a clinically relevant reduction in mortality risk. Given the high mortality risk of people with alcohol dependence, abstinence or a reduction in drinking have been shown to reduce mortality risk and should be considered treatment goals.

References

Aug 1, 1986·British Journal of Addiction·M Sanchez-Craig, H Lei
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Dec 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·E C Harris, B Barraclough
Feb 19, 2002·Journal of Substance Abuse Treatment·Janet A Ambrogne
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Feb 28, 2003·Expert Opinion on Investigational Drugs·W R Miller, J Jackson
Sep 6, 2003·Drug and Alcohol Dependence·Constance WeisnerCharles Moore
May 7, 2004·Acta Psychiatrica Scandinavica. Supplementum·J AlonsoUNKNOWN European Study of the Epidemiology of Mental Disorders (ESEMeD) Project
May 27, 2006·Journal of Psychiatric Practice·Aron N StarostaJoseph R Volpicelli
Nov 24, 2007·Alcoholism, Clinical and Experimental Research·Deborah A DawsonBridget F Grant
Feb 5, 2010·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Nick HeatherUNKNOWN UKATT Research Team
Mar 17, 2010·Journal of Studies on Alcohol and Drugs·Kevin L Delucchi, Constance Weisner
Jul 20, 2010·Drug and Alcohol Review·Jürgen RehmMichael Roerecke
Aug 28, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J RehmU Frick
Mar 28, 2013·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·J Rehm, M Roerecke
Apr 9, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Antoni GualUNKNOWN ESENSE 2 Study Group
May 1, 2013·Addiction·Michael Roerecke, Jürgen Rehm
Jul 23, 2013·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Wim van den BrinkKarl Mann
Jan 9, 2014·Journal of Psychopharmacology·David J Nutt, Jürgen Rehm
Feb 12, 2014·International Journal of Epidemiology·Michael Roerecke, Jürgen Rehm
Oct 25, 2014·European Addiction Research·Jürgen RehmGerhard Gmel
Oct 25, 2014·Journal of Studies on Alcohol and Drugs·Lee Ann KaskutasJason Bond
Apr 4, 2015·European Addiction Research·Henri-Jean AubinJonathan Chick

❮ Previous
Next ❯

Citations

Jan 27, 2016·Expert Opinion on Pharmacotherapy·Michael Soyka
Apr 25, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tim GaekensJohn R Atack
Mar 26, 2016·Frontiers in Psychiatry·Idaira Oliva, Matthew J Wanat
Aug 19, 2016·BMC Medicine·Florian NaudetBruno Laviolle
Nov 16, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl MannWim van den Brink
Dec 26, 2016·Peptides·Richard J Bodnar
Sep 12, 2018·Alcoholism, Clinical and Experimental Research·Justin KnoxUNKNOWN Alcohol Clinical Trials (ACTIVE) Workgroup
Jul 4, 2020·Alcoholism, Clinical and Experimental Research·Justin KnoxUNKNOWN Alcohol Clinical Trials (ACTIVE) Workgroup
Jan 18, 2018·European Addiction Research
Oct 4, 2019·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Carolina BarbosaGary A Zarkin

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00811720
NCT00812461
NCT00811941

Software Mentioned

Stata
Timeline Follow back
BRENDA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.